Evaluation of complete remission (CR) and medical complications with high-dose daunorubicin induction therapy in AML patients treated in Ghazi hospital during 1394-1395 years

Abstract

This study was conducted in patients with acute myeloid leukemia in order to evaluate the effect of a higher dose of daunorubicin on complete remission, overall survival, and disease free survival. Methods: In this observational cohort study, all eligible patients 15-60 years old with newly diagnosed acute myeloid leukemia received 7+3 induction regimen cytarabine 100 mg/m2/d for 7 days and high-dose daunorubicin 90 mg/m2/d for three days.; were studied and collected. Data from the control group were also retrospectively collected from patients with similar conditions that received 7+3 regimen with daunorubicin (45 mg/m2/d). Results: These two groups were similar in demographic and laboratory findings .In our study we did not observe significant difference between standard dose and high dose daunorubicin in overall complete remission as well as overall survival and disease free survival rates. The major side effect of Daunorubicin is a heart failure. Among patients in the treatment group, only one patient had evidence of decreased cardiac function.